Vaxcyte Total Liab from 2010 to 2025
| PCVX Stock | USD 74.66 0.20 0.27% |
Total Liabilities | First Reported 2019-12-31 | Previous Quarter 142.1 M | Current Value 205.5 M | Quarterly Volatility 52.1 M |
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
Vaxcyte | Total Liab |
Latest Vaxcyte's Total Liab Growth Pattern
Below is the plot of the Total Liab of Vaxcyte over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Vaxcyte's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Vaxcyte Total Liab Regression Statistics
| Arithmetic Mean | 62,249,999 | |
| Geometric Mean | 29,200,065 | |
| Coefficient Of Variation | 113.12 | |
| Mean Deviation | 59,417,374 | |
| Median | 40,319,000 | |
| Standard Deviation | 70,415,475 | |
| Sample Variance | 4958.3T | |
| Range | 196.8M | |
| R-Value | 0.72 | |
| Mean Square Error | 2523.1T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 10,717,132 | |
| Total Sum of Squares | 74375.1T |
Vaxcyte Total Liab History
About Vaxcyte Financial Statements
Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 205.5 M | 113 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.